Veru - VERU Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veru in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VERU shares.
View VERU analyst ratings or view top-rated stocks.

5 Wall Street research analysts have issued 12-month price targets for Veru's shares. Their VERU share price forecasts range from $9.00 to $55.00. On average, they predict the company's stock price to reach $28.33 in the next year. This suggests a possible upside of 1,682.0% from the stock's current price.
View analysts price targets for VERU or view top-rated stocks among Wall Street analysts.

Veru's stock was trading at $5.28 at the beginning of 2023. Since then, VERU stock has decreased by 69.9% and is now trading at $1.59.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our VERU earnings forecast.

Veru Inc. (NASDAQ:VERU) posted its quarterly earnings data on Thursday, December, 2nd. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.04. The firm had revenue of $15.65 million for the quarter, compared to analyst estimates of $18.26 million. Veru had a negative trailing twelve-month return on equity of 119.37% and a negative net margin of 412.01%. During the same period in the prior year, the business posted ($0.01) earnings per share.

ETFs with the largest weight of Veru (NASDAQ:VERU) stock in their portfolio include Fidelity MSCI Consumer Staples Index ETF (FSTA), Vanguard Consumer Staples ETF (VDC) and Carbon Collective Climate Solutions U.S. Equity ETF (CCSO) and

Based on aggregate information from My MarketBeat watchlists, some companies that other Veru investors own include Kadmon (KDMN), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Corbus Pharmaceuticals (CRBP), Matinas BioPharma (MTNB), Organigram (OGI), Vaxart (VXRT), Rigel Pharmaceuticals (RIGL), SCYNEXIS (SCYX) and VBI Vaccines (VBIV).

Veru trades on the NASDAQ under the ticker symbol "VERU."

Veru's stock is owned by many different institutional and retail investors. Top institutional investors include Morgan Stanley (9.05%), Geode Capital Management LLC (1.37%), Millennium Management LLC (0.76%), Susquehanna International Group LLP (0.00%), Charles Schwab Investment Management Inc. (0.52%) and Boxer Capital LLC (0.43%). Insiders that own company stock include Harry Fisch, K Gary Barnette, Lucy Lu, Mario Eisenberger, Michele Greco and Mitchell Shuster Steiner.
View institutional ownership trends.

Shares of VERU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VERU stock can currently be purchased for approximately $1.59.

Veru (NASDAQ:VERU) has a market capitalization of $128.25 million and generates $39.35 million in revenue each year. The company earns $-83,780,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis.

The company employs 252 workers across the globe.

Veru's mailing address is 48 NW 25th Street Suite 102, Miami FL, 33127. The official website for the company is www.veruhealthcare.com. The company can be reached via phone at (305) 509-6897, via email at veruinvestor@verupharma.com, or via fax at 312-595-9122.